dolutegravir + tipranavir + ritonavir

This is a **three-drug antiretroviral combination** consisting of the integrase inhibitor **dolutegravir** and the protease inhibitors **tipranavir** and **ritonavir**. Dolutegravir prevents integration of viral DNA into the host genome by inhibiting HIV-1 integrase. Tipranavir is a non-peptidic protease inhibitor targeting HIV-1 protease and is used with ritonavir, which strongly inhibits CYP3A4 and boosts plasma levels of tipranavir. This combination may be considered in the management of **HIV-1 infection** in patients with multiple drug resistances; however, co-administration significantly reduces dolutegravir exposure, so caution and dose adjustments are required[1][2][4][5]. This combination is not a standard, branded, or fixed-dose product but may be used in salvage therapy scenarios under specialist supervision.

Brand names

Tivicay (dolutegravir)Aptivus (tipranavir)Norvir (ritonavir)

Other names

DTG + TPV + RTV